At the news
? NEUTRALIMPACT 3/10 425 filed Nov 2, 2026 at 16:56 ET
InMed announced a 1-for-10 share consolidation conditional on shareholder approval of three proposals at the November 4, 2026 meeting. The consolidation is a procedural step to facilitate the pending merger with Mentari Therapeutics, reducing outstanding shares from 5,493,735 to approximately 549,374. No changes to deal terms or financials were disclosed.
- InMed announced a 1-for-10 share consolidation, reducing outstanding shares from 5,493,735 to approximately 549,374.
- The consolidation is conditional on shareholder approval of the Nasdaq Share Issuance Proposal, Return of Capital Proposal, and Redomestication Proposal at the November 4, 2026 meeting.
- The consolidation is expected to be completed after market close on November 4, 2026, with post-consolidation shares trading on Nasdaq on November 5, 2026.
- This is a procedural step in the previously announced merger with Mentari Therapeutics, with no changes to deal terms or financials.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access